Scapa flows higher on year-end results

0 mins. to read
Scapa flows higher on year-end results
Master Investor Magazine

Never miss an issue of Master Investor Magazine – sign-up now for free!

Read the latest Master Investor Magazine

The price of shares in AIM-listed Scapa (LON:SCPA) is up by 12.01% to 354.50p (as of 12:55 BST) after it announced a 7% increase in revenues for the year ended 31st March, driven by the company’s healthcare arm. Trading profits and margins are in line with expectations.

Chief executive Heejae Chae said: “We reached a milestone of £300 million in revenue and delivered a record profit. In Industrial, we continue to focus on margin improvement and cash generation to support future growth. In Healthcare, the technology transfer of Systagenix’s R&D and manufacturing capabilities from a strategic partner and customer was a transformative transaction. It has enhanced the foundations of our Healthcare strategy and provides the capabilities to deliver long-term sustainable growth as we continue to expand our offering across the complete value chain“.

Take part in our poll

We are reviewing our content and would value you feedback. What types of content would you like to see more of?

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *